Avian influenza A (H5N1) virus infection

References

Key articles

Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008 Jan 17;358(3):261-73.Full text  Abstract

Centers for Disease Control and Prevention. Interim guidance on testing and specimen collection for patients with suspected infection with novel influenza A viruses with the potential to cause severe disease in humans. Mar 2022 [internet publication].Full text

Centers for Disease Control and Prevention. Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. Mar 2022 [internet publication].Full text

World Health Organization. Guidelines for the clinical management of severe illness from influenza virus infections. 2022 [internet publication].Full text

Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses and use of antiviral medications for chemoprophylaxis. Mar 2022 [internet publication].Full text

Reference articles

1. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005 Jan 27;352(4):333-40.Full text  Abstract

2. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet. 2008 Apr 26;371(9622):1427-34. Abstract

3. Skowronski DM, Tweed SA, Petric M, et al. Human illness and isolation of low-pathogenicity avian influenza virus of the H7N3 subtype in British Columbia, Canada. J Infect Dis. 2006 Mar 15;193(6):899-900. Abstract

4. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet. 1999 Sep 11;354(9182):916-7. Abstract

5. Uyeki TM, Chong YH, Katz JM, et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis. 2002 Feb;8(2):154-9.Full text  Abstract

6. Eurosurveillance editorial team. Avian influenza A/(H7N2) outbreak in the United Kingdom. Euro Surveill. 2007 May 31;12(5):E070531.Full text  Abstract

7. Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996 Sep 28;348(9031):901-2. Abstract

8. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004 Dec;10(12):2196-9.Full text  Abstract

9. Nguyen-Van-Tam JS, Nair P, Acheson P, et al. Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. Euro Surveill. 2006 May 4;11(5):E060504.Full text  Abstract

10. Pan M, Gao R, Lv Q, et al. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect. 2016 Jan;72(1):52-9. Abstract

11. Yang ZF, Mok CK, Peiris JS, et al. Human infection with a novel avian influenza A (H5N6) virus. N Engl J Med. 2015 Jul 30;373(5):487-9.Full text  Abstract

12. World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization H5N1 Evolution Working Group. Revised and updated nomenclature for highly pathogenic avian influenza A (H5N1) viruses. Influenza Other Respir Viruses. 2014 May;8(3):384-8.Full text  Abstract

13. World Health Organization. Evolution of the influenza A(H5) haemagglutinin: WHO/OIE/FAO H5 Working Group reports a new clade designated 2.3.4.4. Jan 2015 [internet publication].Full text

14. Smith GJ, Donis RO; World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization (WHO/OIE/FAO) H5 Evolution Working Group. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014. Influenza Other Respir Viruses. 2015 Sep;9(5):271-6.Full text  Abstract

15. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008 Jan 17;358(3):261-73.Full text  Abstract

16. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2010. Wkly Epidemiol Rec. 2011 Apr 22;86(17):161-6.Full text  Abstract

17. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis. 2009 Jul 15;49(2):279-90.Full text  Abstract

18. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005 Feb 17;352(7):686-91.Full text  Abstract

19. Rajabali N, Lim T, Sokolowski C, et al. Avian influenza A (H5N1) infection with respiratory failure and meningoencephalitis in a Canadian traveller. Can J Infect Dis Med Microbiol. 2015 Jul-Aug;26(4):221-3.Full text  Abstract

20. Kandeel A, Manoncourt S, Abd el Kareem E, et al. Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006-2009. Emerg Infect Dis. 2010 Jul;16(7):1101-7.Full text  Abstract

21. International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). Outbreak of mild respiratory disease caused by H5N1 and H9N2 infections among young children in Dhaka, Bangladesh, 2011. Health Sci Bulletin. 2011;9:1-12.Full text

22. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis. 2012 Jul;55(1):26-32.Full text  Abstract

23. Shinde V, Hanshaoworakul W, Simmerman JM, et al. A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006. PLoS One. 2011 Apr 29;6(4):e14809.Full text  Abstract

24. World Health Organization. Surveillance: avian influenza. May 2022 [internet publication].Full text

25. Colorado Department of Public Health and Environment. State health officials investigate a detection of H5 influenza virus in a human in Colorado. Apr 2022 [internet publication].Full text

26. Centers for Disease Control and Prevention. US case of human avian influenza A(H5) virus reported. Apr 2022 [internet publication].Full text

27. UK Health Security Agency. Human case of avian flu detected in UK. 6 Jan 2022 [internet publication].Full text

28. World Health Organization. Update: WHO-confirmed human cases of avian influenza A (H5N1) infection, November 2003-May 2008. Wkly Epidemiol Rec. 2008 Nov 14;83(46):415-20. Abstract

29. UK Health Security Agency. High consequence infectious disease: country specific risk. Oct 2021 [internet publication].Full text

30. Qi Y, Ni HB, Chen X, et al. Seroprevalence of highly pathogenic avian influenza (H5N1) virus infection among humans in mainland China: a systematic review and meta-analysis. Transbound Emerg Dis. 2020 Apr 7 [Epub ahead of print]. Abstract

31. Gomaa MR, El Rifay AS, Abu Zeid D, et al. Incidence and seroprevalence of avian influenza in a cohort of backyard poultry growers, Egypt, Aug 2015-Mar 2019. Emerg Infect Dis. 2020 Sep;26(9):2129-36.Full text  Abstract

32. Centers for Disease Control and Prevention. Highly pathogenic avian influenza A (H5N1) in birds and other animals. Jan 2015 [internet publication].Full text

33. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9(10):e1003657.Full text  Abstract

34. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, et al. Investigation of avian influenza (H5N1) outbreak in humans: Thailand, 2004. MMWR Morb Mortal Wkly Rep. 2006 Apr 28;55(1):3-6.Full text  Abstract

35. Dinh PN, Long HT, Tien NT, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis. 2006 Dec;12(12):1841-7.Full text  Abstract

36. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2011. Wkly Epidemiol Rec. 2012 Mar 30;87(13):117-23.Full text  Abstract

37. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis. 1999 Aug;180(2):505-8. Abstract

38. Zhou L, Liao Q, Dong L, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis. 2009 Jun 15;199(12):1726-34.Full text  Abstract

39. Wan XF, Dong L, Lan Y, et al. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J Virol. 2011 Dec;85(24):13432-8.Full text  Abstract

40. Cavailler P, Chu S, Ly S, et al. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J Clin Virol. J Clin Virol. 2010 Jun;48(2):123-6. Abstract

41. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet. 2008 Aug 30;372(9640):744-9. Abstract

42. Horby P, Sudoyo H, Viprakasit V, et al. What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1? Epidemiol Infect. 2010 Nov;138(11):1550-8.Full text  Abstract

43. Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007. Wkly Epidemiol Rec. 2008 Oct 3;83(40):359-64. Abstract

44. Aditama TY, Samaan G, Kusriastuti R, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis. 2011 Dec;53(12):1237-44.Full text  Abstract

45. Aditama TY, Samaan G, Kusriastuti R, et al. Avian influenza H5N1 transmission in households, Indonesia. PLoS One. 2012;7(1):e29971.Full text  Abstract

46. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006 Nov 23;355(21):2186-94.Full text  Abstract

47. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005 Sep 29;353(13):1374-85.Full text  Abstract

48. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012 May 2;486(7403):420-8.Full text  Abstract

49. Neumann G, Macken CA, Karasin AI, et al. Egyptian H5N1 influenza viruses-cause for concern? PLoS Pathog. 2012;8(11):e1002932.Full text  Abstract

50. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science. 2012 Jun 22;336(6088):1541-7.Full text  Abstract

51. Uyeki TM, Bresee JS. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007 Dec;13(12):1969-71.Full text  Abstract

52. Refaey S, Azziz-Baumgartner E, Amin MM, et al. Increased number of human cases of influenza virus A(H5N1) infection, Egypt, 2014-15. Emerg Infect Dis. 2015 Dec;21(12):2171-3.Full text  Abstract

53. Le MQ, Horby P, Fox A, et al. Subclinical avian influenza A(H5N1) virus infection in human, Vietnam. Emerg Infect Dis. 2013 Oct;19(10):1674-7.Full text  Abstract

54. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009 Jul 10;325(5937):197-201.Full text  Abstract

55. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005 Aug;3(8):591-600. Abstract

56. Yamada S, Suzuki Y, Suzuki T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature. 2006 Nov 16;444(7117):378-82. Abstract

57. van Riel D, Munster VJ, de Wit E, et al. H5N1 virus attachment to lower respiratory tract. Science. 2006 Apr 21;312(5772):399. Abstract

58. Shu Y, Li CK, Li Z, et al. Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues. J Infect Dis. 2010;201:1173-1177. Abstract

59. Chandrasekaran A, Srinivasan A, Raman R, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008 Jan;26(1):107-13. Abstract

60. Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol. 2007 Sep;81(18):9950-5.Full text  Abstract

61. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005 Nov 11;6(1):135.Full text  Abstract

62. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006 Oct;12(10):1203-7.Full text  Abstract

63. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet. 2007 Sep 29;370(9593):1137-45. Abstract

64. Apisarnthanarak A, Erb S, Stephenson I, et al. Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center. Clin Infect Dis. 2005 Jan 15;40(2):e16-8. Abstract

65. Liem NT, Lim W. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis. 2005 Feb;11(2):210-5.Full text  Abstract

66. Schultsz C, Dong VC, Chau NV, et al. Avian influenza H5N1 and healthcare workers. Emerg Infect Dis. 2005 Jul;11(7):1158-9.Full text  Abstract

67. Ortiz JR, Katz MA, Mahmoud MN, et al. Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. J Infect Dis. 2007 Dec 1;196(11):1685-91.Full text  Abstract

68. Prieto-Lara E, Llanos-Mendez A. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. Vaccine. 2010 Jun 11;28(26):4328-34. Abstract

69. Vesikari T, Forstén A, Herbinger KH, et al. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine. 2012 Feb 8;30(7):1388-96. Abstract

70. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011 Jun 15;203(12):1729-38.Full text  Abstract

71. US Food and Drug Administration. Influenza virus vaccine, H5N1 (for national stockpile). Feb 2018 [internet publication].Full text

72. Qualls N, Levitt A, Kanade N, et al; CDC Community Mitigation Guidelines Work Group. Community mitigation guidelines to prevent pandemic influenza - United States, 2017. MMWR Recomm Rep. 2017 Apr 21;66(1):1-34.Full text  Abstract

73. Centers for Disease Control and Prevention. Case definitions for investigations of human infection with avian influenza A viruses in the United States. Mar 2022 [internet publication].Full text

74. World Health Organization. Interim guidelines for avian influenza case management. Sep 2007 [internet publication].Full text

75. Centers for Disease Control and Prevention. Interim guidance on testing and specimen collection for patients with suspected infection with novel influenza A viruses with the potential to cause severe disease in humans. Mar 2022 [internet publication].Full text

76. Centers for Disease Control and Prevention. Interim guidance for infection control within healthcare settings when caring for confirmed cases, probable cases, and cases under investigation for infection with novel influenza A viruses associated with severe disease. Mar 2022 [internet publication].Full text

77. World Health Organization. Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection. Oct 2006 [internet publication].Full text

78. Centers for Disease Control and Prevention. Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. Mar 2022 [internet publication].Full text

79. World Health Organization. Guidelines for the clinical management of severe illness from influenza virus infections. 2022 [internet publication].Full text

80. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red book: 2006 report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:561.

81. UK Health Security Agency. Avian influenza: guidance for managing human cases. Nov 2021 [internet publication].Full text

82. Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses and use of antiviral medications for chemoprophylaxis. Mar 2022 [internet publication].Full text

83. Centers for Disease Control and Prevention. Interim guidance on influenza antiviral chemoprophylaxis of persons exposed to birds with avian influenza A viruses associated with severe human disease or with the potential to cause severe human disease. Mar 2022 [internet publication].Full text

84. Patel RB, Mathur MB, Gould M, et al. Demographic and clinical predictors of mortality from highly pathogenic avian influenza A (H5N1) virus infection: CART analysis of international cases. PLoS One. 2014 Mar 25;9(3):e91630.Full text  Abstract

85. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Feb 2022 [internet publication].Full text

86. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010 Oct 15;202(8):1154-60.Full text  Abstract

87. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012 Nov;206(9):1359-66. Abstract

88. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010 Nov 2;7(11):e1000362.Full text  Abstract

89. Kayali G, Webby RJ, Ducatez MF, et al. The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt. PLoS One. 2011 Mar 21;6(3):e17730.Full text  Abstract

90. Fiebig L, Soyka J, Buda S, et al. Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010. Euro Surveill. 2011 Aug 11;16(32):19941.Full text  Abstract

91. Arabi Y, Gomersall CD, Ahmed QA, et al. The critically ill avian influenza A (H5N1) patient. Crit Care Med. 2007 May;35(5):1397-403. Abstract

92. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667-2672.Full text  Abstract

93. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005 Oct 20;437(7062):1108. Abstract

94. Le MT, Wertheim HF, Nguyen HD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One. 2008 Oct 6;3(10):e3339.Full text  Abstract

95. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008;3(10):e3410.Full text  Abstract

96. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007 Oct 4;357(14):1450-1.Full text  Abstract

97. Yu H, Gao Z, Feng Z, et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One. 2008 Aug 21;3(8):e2985.Full text  Abstract

98. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J infect Dis. 2015 Jan 1;211(1):80-90.Full text  Abstract

99. Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97.Full text  Abstract

100. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. 2007 Apr;27(4):494-503.Full text  Abstract

101. Lee CM, Hudson LD. Long-term outcomes after ARDS. Semin Respir Crit Care Med. 2001 Jun;22(3):327-36. Abstract

102. Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA. 2010 Feb 24;303(8):763-70.Full text  Abstract

Use of this content is subject to our disclaimer